Breast Cancer Clinical Case

A 59-year-old postmenopausal female underwent a partial mastectomy and sentinel lymph node biopsy (SLNB) for a 1.5 cm right breast moderately-differentiated invasive ductal carcinoma, ER 100%, PR 90%, HER2 positive (3+), with 0/1 positive lymph nodes.

What would you do next?

The 21-gene signature is only indicated for HR+ / HER2 negative tumors.

For small node-negative HER2 positive tumors, paclitaxel and trastuzumab are recommended

References

1. Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. New Engl J Med. 2015;372(2):134-141.

2. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s